Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/24/2017 Date
55.2(c) 54.1(c) 54.27(c) 54.37(c) 54.35(c) Last
9 884 066 17 178 688 13 711 279 7 376 233 4 341 296 Volume
+0.05% -1.99% +0.31% +0.18% -0.04% Change
More quotes
Financials ($)
Sales 2017 40 235 M
EBIT 2017 13 724 M
Net income 2017 5 243 M
Debt 2017 12 104 M
Yield 2017 3,48%
Sales 2018 41 050 M
EBIT 2018 14 115 M
Net income 2018 8 224 M
Debt 2018 12 287 M
Yield 2018 3,56%
P/E ratio 2017 26,30
P/E ratio 2018 17,09
EV / Sales2017 3,99x
EV / Sales2018 3,91x
Capitalization 148 B
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
12/09Presentation
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
11/23 BioLineRx Reports Third Quarter 2017 Financial Results
11/22 MERCK AND : BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted..
11/22 ROCHE : Lung cancer data gives Roches Tecentriq a boost
11/22 MERCK AND : Startup wants to repurpose an old drug Startup wants to bring back V..
11/21 THE LATEST : Startup could bring back Vioxx for hemophilia
11/21 APNEWSBREAK : Startup could bring back Vioxx for hemophilia
11/21 MERCK AND : Technology, retail send stocks higher
11/21 MERCK AND : Startup wants to bring back Vioxx for hemophilia joint pain
11/17 MERCK AND : ACC, John L. Weinberg Center for Corporate Governance Interview Merc..
11/16 MERCK AND : StayWells Krames On FHIR App Listed in App Orchard
More news
Sector news : Pharmaceuticals - NEC
11/23 German chemicals companies should review British ops - trade body
11/23DJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
11/22 FTSE gets sterling boost, land purchase threat dents housebuilders
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on MERCK AND COMPANY 
MERCK & CO., INC. - 2013
A resistance as obstacle
SELL
More Strategies
News from SeekingAlpha
11/22 REPORT : UPS license lets it get into pharma supply chain
11/22 GILEAD : Buying New Growth
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
11/20 Roche Rocks On With More Good News
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 65,4 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-7.64%148 286
JOHNSON & JOHNSON20.08%368 832
NOVARTIS12.75%219 874
ROCHE HOLDING LTD.4.90%215 394
PFIZER9.42%211 188
AMGEN16.16%123 376